Cargando…

GEO Data Mining Identifies OLR1 as a Potential Biomarker in NSCLC Immunotherapy

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. The tumor immune microenvironment (TME) in NSCLC is closely correlated to tumor initiation, progression, and prognosis. TME failure impedes the generation of an effective antitumor immune response. In this study, we attempted...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Bin, Wang, Ziyu, Gu, Meng, Zhao, Cong, Ma, Teng, Wang, Jinghui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8095246/ https://www.ncbi.nlm.nih.gov/pubmed/33959497 http://dx.doi.org/10.3389/fonc.2021.629333

Ejemplares similares

A Novel Lipid Prognostic Signature of ADCY2, LIPE, and OLR1 in Head and Neck Squamous Cell Carcinoma
por: Gao, Xiaolei, et al.
Publicado: (2021)

Screening of immunotherapy-related genes in bladder cancer based on GEO datasets
por: Liu, Xiaolong, et al.
Publicado: (2023)

The Landscape of Immunotherapy Resistance in NSCLC
por: Frisone, Daniele, et al.
Publicado: (2022)

Recent Advances in Immunotherapy in Metastatic NSCLC
por: Bansal, Pranshu, et al.
Publicado: (2016)

Erratum: The landscape of immunotherapy resistance in NSCLC
Publicado: (2023)

Mining GEO and TCGA Database for Immune Microenvironment of Lung Squamous Cell Carcinoma Patients With or Without Chemotherapy
por: Qiang, Huiping, et al.
Publicado: (2022)

Immunotherapy in NSCLC Patients With Brain and Leptomeningeal Metastases
por: Pierret, Thomas, et al.
Publicado: (2022)

Editorial: Immunotherapy for NSCLC with oncogenic driver variants
por: Du, Yijia, et al.
Publicado: (2022)

Current status and challenges of immunotherapy in ALK rearranged NSCLC
por: Qi, Rongbin, et al.
Publicado: (2022)

Research Progress of Anti-PD-1/PD-L1 Immunotherapy Related Mechanisms and Predictive Biomarkers in NSCLC
por: Bie, Fenglong, et al.
Publicado: (2022)

GEO data mining identifies potential immune-related genes in hypertrophic scar and verities in a rabbit model
por: Cai, Hong, et al.
Publicado: (2023)

Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China
por: Xiong, Anwen, et al.
Publicado: (2021)

Microenvironment and the progress of immunotherapy in clinical practice of NSCLC brain metastasis
por: Xie, Mengqing, et al.
Publicado: (2023)

Long-Read Sequencing Annotation of the Transcriptome in DNA-PK Inactivated Cells
por: Song, Liwei, et al.
Publicado: (2022)

Comparison of Efficacy and Safety Between Immunotherapy and Docetaxel Monotherapy in NSCLC Patients
por: Yang, Wenchao, et al.
Publicado: (2022)

PET/CT Radiomic Features: A Potential Biomarker for EGFR Mutation Status and Survival Outcome Prediction in NSCLC Patients Treated With TKIs
por: Yang, Liping, et al.
Publicado: (2022)

Co-Occurring Alteration of NOTCH and DDR Pathways Serves as Novel Predictor to Efficacious Immunotherapy in NSCLC
por: Zhang, Zhimin, et al.
Publicado: (2021)

m(6)A regulators featured by tumor immune microenvironment landscapes and correlated with immunotherapy in non-small cell lung cancer (NSCLC)
por: Yuan, Baowen, et al.
Publicado: (2022)

Acquired resistance to EGFR-TKIs in NSCLC mediates epigenetic downregulation of MUC17 by facilitating NF-κB activity via UHRF1/DNMT1 complex
por: Lin, Shuye, et al.
Publicado: (2023)

Review of biomarkers for response to immunotherapy in HNSCC microenvironment
por: Chen, Shaoshi, et al.
Publicado: (2023)

CCNF is a potential pancancer biomarker and immunotherapy target
por: Wei, Lifang, et al.
Publicado: (2023)

Tissue MicroRNA Expression as a Predictor of Response to Immunotherapy in NSCLC Patients
por: Grenda, Anna, et al.
Publicado: (2021)

Association of sarcopenia with survival in advanced NSCLC patients receiving concurrent immunotherapy and chemotherapy
por: Bolte, Fabian J., et al.
Publicado: (2022)

Efficacy of immunotherapy in KRAS-mutant advanced NSCLC: A real-world study in a Chinese population
por: Peng, Lixiu, et al.
Publicado: (2023)

Acute Phase Proteins as Early Predictors for Immunotherapy Response in Advanced NSCLC: An Explorative Study
por: Schneider, Marc A., et al.
Publicado: (2022)

Immunotherapy combined with rh-endostatin improved clinical outcomes over immunotherapy plus chemotherapy for second-line treatment of advanced NSCLC
por: Huang, Hongxiang, et al.
Publicado: (2023)

Smoking and Lung Cancer: A Geo-Regional Perspective
por: Rahal, Zahraa, et al.
Publicado: (2017)

Editorial: Emerging Biomarkers for NSCLC: Recent Advances in Diagnosis and Therapy
por: Malapelle, Umberto, et al.
Publicado: (2021)

Progress on neoadjuvant immunotherapy in resectable non-small cell lung cancer and potential biomarkers
por: Wu, Xinyu, et al.
Publicado: (2023)

Immunotherapy strategies for EGFR-mutated advanced NSCLC after EGFR tyrosine-kinase inhibitors failure
por: Li, Xingyuan, et al.
Publicado: (2023)

Failure to replicate an association of SNPs in the oxidized LDL receptor gene (OLR1) with CAD
por: Knowles, Joshua W, et al.
Publicado: (2008)

OLR1 Gene Polymorphism and Oxidized LDL Levels in Metabolic Syndrome in Indian Population
por: Jamatia, Elvia, et al.
Publicado: (2018)

Mining the Gut Microbiota for Microbial-Based Therapeutic Strategies in Cancer Immunotherapy
por: Li, Bolei, et al.
Publicado: (2021)

YTHDF1 Is a Potential Pan-Cancer Biomarker for Prognosis and Immunotherapy
por: Hu, Jian, et al.
Publicado: (2021)

Radiolabeled EGFR TKI as predictive imaging biomarkers in NSCLC patients – an overview
por: Van De Stadt, Eveline, et al.
Publicado: (2022)

Pan-Cancer Analysis of the Oncogenic and Immunological Role of RCN3: A Potential Biomarker for Prognosis and Immunotherapy
por: Ding, Jian, et al.
Publicado: (2022)

Circulating Biomarkers for Prediction of Immunotherapy Response in NSCLC
por: Goh, Kah Yee, et al.
Publicado: (2023)

Chemo-immunotherapy for metastatic non-squamous NSCLC in a patient with HIV infection: A case report
por: Inno, Alessandro, et al.
Publicado: (2023)

DDX60 Is Associated With Glioma Malignancy and Serves as a Potential Immunotherapy Biomarker
por: Zhang, Jingwen, et al.
Publicado: (2021)

Case Report: An “Immune-Cold” EGFR Mutant NSCLC With Strong PD-L1 Expression Shows Resistance to Chemo-Immunotherapy
por: Zhao, Qian, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_notii6njg5ip2r56mr87cl9o4n